1,3-Benzodioxolyl-N-ethylbutanamine

1,3-Benzodioxolyl-N-ethylbutanamine (BDB, Eve) is a psychoactive drug and member of the phenethylamine chemical class which acts as an entactogen, psychedelic, and stimulant. It is structurally analogous to methylenedioxymethamphetamine (MDMA).

History

BDB was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines I Have Known And Loved), the dosage range is listed as 150–230 mg and the duration is listed as 4–8 hours. While pleasant and euphoric, BDB is also described as less intense than MDMA.

Pharmacology

The mechanism of action for BDB is similar to that of MDMA, but the ratio of serotonin release versus dopamine and norepinephrine release is different. BDB is a more balanced releaser of serotonin, norepinephrine, and dopamine when compared to MDMA.

Effects

The effects of BDB can vary by dosage, and include feelings of love and empathy, increased awareness of senses, and emotional introspection. Side effects can include anxiety, paranoia, and restlessness.

Legal Status

BDB is a controlled substance in several countries, including the United States and the United Kingdom.

See Also

• Phenethylamine
• MDMA
• Alexander Shulgin
• PiHKAL

References

• Shulgin, Alexander; Ann Shulgin (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5.

   This article is a Psychoactive drug-related stub. You can help WikiMD by expanding it!